Senesco Appoints Harlan W. Waksal, M.D., to Board of... ( Co-founder of and Former Senior E...)

Senesco Appoints Harlan W. Waksal, M.D., to Board of Directors

Date:10/29/2008

Co-founder of and Former Senior Executive at ImClone Brings Substantial Oncology Drug Development Expertise

NEW BRUNSWICK, N.J., Oct. 29 /PRNewswire-FirstCall/ -- Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE Alternext US: SNT) announced today the appointment of Harlan W. Waksal, M.D., 55 to its board of directors. Senesco's board of directors now consists of nine members, seven of whom are independent.

(Photo: http://www.newscom.com/cgi-bin/prnh/20081029/NY42202 )

Dr. Waksal is the President and Sole Proprietor of Waksal Consulting L.L.C., which was founded in 2003 and provides strategic business and clinical development counsel to biotechnology companies. Dr. Waksal co-founded the biotechnology company, ImClone Systems Incorporated, in 1984. He served at ImClone in a variety of senior roles over a 16 year period, beginning in 1987. During his tenures as Chief Operating Officer, from 1987 through 2002, and Chief Executive Officer, from 2002 until 2003, Dr. Waksal was instrumental in moving forward the clinical development program for ERBITUX(R) (cetuximab), an oncology drug now approved in colorectal and head & neck cancers. ERBITUX (cetuximab) is a monoclonal antibody (IgG1 Mab) designed to inhibit the function of a molecular structure expressed on the surface of normal and tumor cells, called the epidermal growth factor receptor (EGFR).

"Senesco is very pleased to have Dr. Waksal join our Board," said Rudolf Stalder, Chairman of Senesco's Board. "His significant contribution to the clinical development of Erbitux, and vast knowledge of the oncology space, will provide critical industry insight to Senesco."

"We look forward to working with Dr. Waksal as we move toward our goal of filing an IND for multiple myeloma," said Bruce Galton, President & Chief Executive Officer of Senesco. "We believe his extensive and distinguished wo
'/>"/>

0

GOOD

Page: 1 2 3
Related biology technology :

1. Senescos Preclinical Multiple Myeloma Data to be Presented at the 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
2. Senesco Technologies Announces Successful Completion of First Milestone Related to Agreement with Bayer CropScience
3. Senesco Technologies Closes Remaining $3.0 Million of Previously Announced Financing
4. Senesco Signs a Supply Agreement for Polyplus-transfections Delivery System
5. Senesco Technologies to Present at BIO 2008 Business Forum
6. Senesco Technologies Reports Third Quarter Fiscal 2008 Financial Results
7. Senesco Technologies Regains Compliance With Amexs Continued Listing Requirements
8. Senesco Technologies Reports Second Quarter Fiscal 2008 Financial Results
9. Senesco Technologies Reports on Results of Preclinical Multiple Myeloma Studies
10. Senesco Technologies Closes on Additional $4.0 Million of Previously Announced Financing
11. Boston Healthcare Appoints Adam Barak as Vice President Enhancing Its International Pricing and Reimbursement Capability

Post Your Comments:

Senesco Appoints Harlan W. Waksal, M.D., to Board of...( Co-founder of and Former Senior E...)